The global psoriasis biosimilars market is valued at USD 10.46 billion in 2025 and is projected to reach USD 27.22 billion by 2034, growing at a CAGR of 11.21%. Growth is driven by the rising incidence of psoriasis, increasing affordability of biosimilars compared to biologics, and supportive government and insurance policies.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Psoriasis Biosimilars Industry Impact
5.2. COVID -19 Impact Assessment for the Industry
5.3. COVID - 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Psoriasis Biosimilars Market Revenue and Volume Forecast, by Drug Class
8.1.1. TNF-Alpha Inhibitors
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Infliximab
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Etanercept
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Adalimumab
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Other Biosimilars
8.1.5.1. Market Revenue and Volume Forecast
9.1. Psoriasis Biosimilars Market Revenue and Volume Forecast, by Indication
9.1.1. Plaque Psoriasis
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Psoriatic Arthritis
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Other Types
9.1.3.1. Market Revenue and Volume Forecast
10.1. Psoriasis Biosimilars Market Revenue and Volume Forecast, by Route of Administration
10.1.1. Subcutaneous
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Intravenous
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Oral
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Topical
10.1.4.1. Market Revenue and Volume Forecast
11.1. Psoriasis Biosimilars Market Revenue and Volume Forecast, by Sales Channel
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Retail Pharmacy Chains
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Drug Class
12.1.2. Market Revenue and Volume Forecast, by Indication
12.1.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.4. Market Revenue and Volume Forecast, by Sales Channel
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Drug Class
12.1.5.2. Market Revenue and Volume Forecast, by Indication
12.1.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.5.4. Market Revenue and Volume Forecast, by Sales Channel
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Drug Class
12.1.6.2. Market Revenue and Volume Forecast, by Indication
12.1.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.1.6.4. Market Revenue and Volume Forecast, by Sales Channel
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Drug Class
12.2.2. Market Revenue and Volume Forecast, by Indication
12.2.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.4. Market Revenue and Volume Forecast, by Sales Channel
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Drug Class
12.2.5.2. Market Revenue and Volume Forecast, by Indication
12.2.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.5.4. Market Revenue and Volume Forecast, by Sales Channel
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Drug Class
12.2.6.2. Market Revenue and Volume Forecast, by Indication
12.2.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.6.4. Market Revenue and Volume Forecast, by Sales Channel
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Drug Class
12.2.7.2. Market Revenue and Volume Forecast, by Indication
12.2.7.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.7.4. Market Revenue and Volume Forecast, by Sales Channel
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Drug Class
12.2.8.2. Market Revenue and Volume Forecast, by Indication
12.2.8.3. Market Revenue and Volume Forecast, by Route of Administration
12.2.8.4. Market Revenue and Volume Forecast, by Sales Channel
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Drug Class
12.3.2. Market Revenue and Volume Forecast, by Indication
12.3.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.4. Market Revenue and Volume Forecast, by Sales Channel
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Drug Class
12.3.5.2. Market Revenue and Volume Forecast, by Indication
12.3.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.5.4. Market Revenue and Volume Forecast, by Sales Channel
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Drug Class
12.3.6.2. Market Revenue and Volume Forecast, by Indication
12.3.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.6.4. Market Revenue and Volume Forecast, by Sales Channel
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Drug Class
12.3.7.2. Market Revenue and Volume Forecast, by Indication
12.3.7.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.7.4. Market Revenue and Volume Forecast, by Sales Channel
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Drug Class
12.3.8.2. Market Revenue and Volume Forecast, by Indication
12.3.8.3. Market Revenue and Volume Forecast, by Route of Administration
12.3.8.4. Market Revenue and Volume Forecast, by Sales Channel
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Drug Class
12.4.2. Market Revenue and Volume Forecast, by Indication
12.4.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.4. Market Revenue and Volume Forecast, by Sales Channel
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Drug Class
12.4.5.2. Market Revenue and Volume Forecast, by Indication
12.4.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.5.4. Market Revenue and Volume Forecast, by Sales Channel
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Drug Class
12.4.6.2. Market Revenue and Volume Forecast, by Indication
12.4.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.6.4. Market Revenue and Volume Forecast, by Sales Channel
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Drug Class
12.4.7.2. Market Revenue and Volume Forecast, by Indication
12.4.7.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.7.4. Market Revenue and Volume Forecast, by Sales Channel
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Drug Class
12.4.8.2. Market Revenue and Volume Forecast, by Indication
12.4.8.3. Market Revenue and Volume Forecast, by Route of Administration
12.4.8.4. Market Revenue and Volume Forecast, by Sales Channel
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Drug Class
12.5.2. Market Revenue and Volume Forecast, by Indication
12.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.5.4. Market Revenue and Volume Forecast, by Sales Channel
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Drug Class
12.5.5.2. Market Revenue and Volume Forecast, by Indication
12.5.5.3. Market Revenue and Volume Forecast, by Route of Administration
12.5.5.4. Market Revenue and Volume Forecast, by Sales Channel
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Drug Class
12.5.6.2. Market Revenue and Volume Forecast, by Indication
12.5.6.3. Market Revenue and Volume Forecast, by Route of Administration
12.5.6.4. Market Revenue and Volume Forecast, by Sales Channel
13.1. Merck KGaA
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Gyros Protein Technologies AB
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Pfizer Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Novartis International AG
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Amgen Inc
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Abbott
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Fresenius Kabi
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Viatris
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Reddy's Laboratories
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. GenScript
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description